BioNTech, Scancell to discover TCR therapies for cancer

BioNTech AG (Mainz, Germany) and Scancell Holdings plc (LSE:SCLP; FSE:SCP) partnered to identify and develop T cell receptor (TCR) therapies to treat cancer.

The partners plan to identify TCRs specific for citrullinated epitopes from vimentin (VIM) and enolase using Scancell's Moditope immunotherapy platform and BioNTech's platform technology for high-throughput cloning and characterization of naturally selected TCRs. These epitopes form the basis of Scancell's Modi-1, which is preclinical development for cancer...